公司资料
Moderna, Inc. 股价、新闻与催化剂
- 股票代码:
- MRNA
- 交易所:
- NASDAQ
- 行业:
- Nucleic Acid Drugs
- 所在地:
- United States
股票表现
64.46 USD (+1.80%)
收盘价
最后更新: 2026年8月17日
18.1B USD
市值
股价为何变动
As of Aug 17, 2026, MRNA closed up 1.80% at $64.46. No new same-company headline was identified in the current news window.
公司概览
业务概览
Moderna is a biotechnology company built around messenger RNA, with major programs spanning infectious disease, oncology, rare disease, and immunology. The company’s identity is defined by its platform and the market’s ongoing view of whether mRNA can keep producing high-value medicines.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, Moderna is a platform biotech with a global commercial reach. It sits in the innovation-heavy part of biotechnology rather than mature pharma.
商业模式特征
Moderna combines platform-driven R&D with product commercialization, manufacturing scale, and broad pipeline optionality. Investors focus on vaccine demand, pipeline readouts, launch execution, and whether the platform can deliver durable post-pandemic growth.
生物医药行业定位
Moderna sits near the center of modern platform biotech because it combines scientific novelty with real commercial visibility. The stock is highly sensitive to pipeline updates, regulatory milestones, and platform confidence.
未来催化剂
- Moderna’s key catalysts are the flu/COVID combo vaccine program, CMV vaccine data, and the Merck-partnered cancer-vaccine program. That readout matters because it decides whether the asset is ready for a larger and more expensive development step. If the data come in cleanly, the market tends to give the broader platform behind the program more credit.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。